Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)-Reference-Cited by-同舟云学术

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Published:2017-02-09 Issue:4 Volume:7 Page:400-409
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Drilon Alexander,Siena Salvatore,Ou Sai-Hong Ignatius,Patel Manish,Ahn Myung Ju,Lee Jeeyun,Bauer Todd M.,Farago Anna F.,Wheler Jennifer J.,Liu Stephen V.,Doebele Robert,Giannetta Laura,Cerea Giulio,Marrapese Giovanna,Schirru Michele,Amatu Alessio,Bencardino Katia,Palmeri Laura,Sartore-Bianchi Andrea,Vanzulli Angelo,Cresta Sara,Damian Silvia,Duca Matteo,Ardini Elena,Li Gang,Christiansen Jason,Kowalski Karey,Johnson Ann D.,Patel Rupal,Luo David,Chow-Maneval Edna,Hornby Zachary,Multani Pratik S.,Shaw Alice T.,De Braud Filippo G.

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 678 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals;Current Problems in Cancer;2024-12

2. Overcoming therapy resistance in pancreatic cancer: New insights and future directions;Biochemical Pharmacology;2024-11

3. Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer;Anti-Cancer Drugs;2024-08-21

4. Progress in histology specific treatments in soft tissue sarcoma;Expert Review of Anticancer Therapy;2024-08-05

5. Molecular and Pathological Features of Paediatric High-Grade Gliomas;International Journal of Molecular Sciences;2024-08-03